Volume-2 ,Issue-6, June- 2026

The present study focused on the development and evaluation of a nanoemulsion-based delivery system of Erlotinib to enhance its solubility, dissolution, and bioavailability. Nanoemulsions were prepared by the ultrasonication method using Capryol 90, Tween 80, and PEG 400/propylene glycol as oil, surfactant, and co-surfactant, respectively. Preformulation studies confirmed suitable physicochemical and flow properties of the drug for lipid-based delivery. Ten formulations (F1–F10) were optimized and evaluated for droplet size, PDI, zeta potential, drug content, encapsulation efficiency, in vitro release, and stability. The optimized formulations showed nanosized droplets (107–145 nm), low PDI (0.16–0.23), high drug content (95.5–97.8%), and good encapsulation efficiency (90.8–94.1%). In vitro studies demonstrated significantly enhanced and sustained drug release (up to 97–99% in 24 h) compared to the marketed product (75%). Stability studies confirmed minimal changes in key parameters, indicating good formulation stability. Overall, the developed nanoemulsion significantly improved the solubility, dissolution, and release profile of Erlotinib, suggesting enhanced potential for oral bioavailability and anticancer efficacy.

Keyword: Erlotinib, Nanoemulsion, Poor solubility, Bioavailability enhancement, Ultrasonication, Capryol 90